Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03273413 · ClinicalTrials.gov registry record · Phase 4
Statin Therapy in Patients With Early Stage ADPKD
A Phase 4 study of Autosomal Dominant Polycystic Kidney and ADPKD, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03273413 is a Phase 4 study of Autosomal Dominant Polycystic Kidney and ADPKD that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 150 participants, above the 80-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (88% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03273413, a Phase 4 study of Autosomal Dominant Polycystic Kidney and ADPKD, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this study as an investigational drug for treatment of ADPKD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pravastatin
Study Locations (1)
Colorado
- University of Colorado Denver Anschutz Medical Campus - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-08-31 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03273413
The ClinicalTrials.gov registry entry for NCT03273413 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 80-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (88% higher). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Autosomal Dominant Polycystic Kidney appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03273413 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03273413 about?
NCT03273413 is a clinical study titled "Statin Therapy in Patients With Early Stage ADPKD". This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high choleste...
What is the current status of trial NCT03273413?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2017-08-31. Estimated completion is 2025-09-30.
What conditions does trial NCT03273413 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney, ADPKD.
What interventions are being tested in trial NCT03273413?
The interventions under investigation include: Placebo (DRUG), Pravastatin (DRUG).
Who is sponsoring clinical trial NCT03273413?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03273413 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
RECRUITING · Phase 2
-
A Prospective Observational Study of Foam Sclerotherapy .
RECRUITING
-
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
-
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.